Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment

Review

(2776) Views  (648) Full article downloads

Authors: Claudia Gagnon, Vivien Li, Peter R Ebeling

Published Date August 2008 Volume 2008:3(4) Pages 635 - 645

DOI: http://dx.doi.org/10.2147/CIA.S3372

Claudia Gagnon, Vivien Li, Peter R Ebeling

Department of Medicine, University of Melbourne, Melbourne, Australia

Abstract: As the population ages, the burden of osteoporosis in men is expected to rise. Implementation of preventive measures such as falls prevention strategies, exercise and adequate calcium and vitamin D intake is recommended. However, when the diagnosis of osteoporosis is made, effective treatments need to be initiated to prevent fractures. As opposed to postmenopausal women, reduced bone formation is the predominant mechanism of age-related bone loss in men, making anabolic agents a logical treatment option for men with osteoporosis. Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men. This paper summarizes the mechanism of action of teriparatide, as well as its tolerability and safety. Furthermore, the evidence supporting the efficacy of teriparatide treatment in men with osteoporosis is reviewed and its current role in the management of osteoporosis in men is discussed.

Keywords: osteoporosis, pathophysiology, treatment, parathyroid hormone, men